Back to resultsMemantine in Patients With Chronic Glaucoma
Primary Purpose
Open-Angle Glaucoma
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
memantine
Sponsored by
About this trial
This is an interventional treatment trial for Open-Angle Glaucoma
Eligibility Criteria
Inclusion Criteria: glaucoma damage on examination of visual field and optic disc good visual acuity (with glasses if needed)
Sites / Locations
Outcomes
Primary Outcome Measures
Progression of glaucoma
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00168350
Brief Title
Memantine in Patients With Chronic Glaucoma
Study Type
Interventional
2. Study Status
Record Verification Date
November 2010
Overall Recruitment Status
Completed
Study Start Date
March 2000 (undefined)
Primary Completion Date
September 2006 (Actual)
Study Completion Date
September 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Allergan
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Randomized double-masked clinical trial of memantine in patients with glaucoma
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open-Angle Glaucoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1179 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
memantine
Primary Outcome Measure Information:
Title
Progression of glaucoma
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
82 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
glaucoma damage on examination of visual field and optic disc
good visual acuity (with glasses if needed)
12. IPD Sharing Statement
Learn more about this trial
Memantine in Patients With Chronic Glaucoma
We'll reach out to this number within 24 hrs